Compare ZDGE & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | IMMP |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | Australia |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 31.5M |
| IPO Year | 2016 | 2012 |
| Metric | ZDGE | IMMP |
|---|---|---|
| Price | $2.71 | $3.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.9K | ★ 154.6K |
| Earning Date | 10-26-2026 | 09-01-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 73.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,398,000.00 | N/A |
| Revenue This Year | $6.30 | N/A |
| Revenue Next Year | $0.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.21 | $0.26 |
| 52 Week High | $4.70 | $5.36 |
| Indicator | ZDGE | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 59.14 |
| Support Level | $2.57 | $2.65 |
| Resistance Level | $3.14 | $5.36 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 0.00 | 5.22 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.